PolyNovo: Success in producing human insulin

Company News

by Jessica Amir

PolyNovo (ASX:PNV) has announced it has progressed its specialised skin cell research project, which produces insulin under the skin for people with type I diabetes.

The medical innovation company, in collaboration with Beta Cell Technologies, received successful results from the trial of NovoSorb BTM in pigs.

In the trial, islet cells from the pancreas were implanted into NovoSorb BTMs which help to produce human insulin and reduce rejection.

PolyNovo says it’s exciting proof and potentially an early step in creating a ‘dermal depot’ in the skin, which potentially removes the need for insulin injections in type 1 diabetes sufferers.

Shares in PolyNovo (ASX:PNV) opened 4.55% higher to 23 cents.
 

Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 after having worked in financial advising for seven years and in TV journalism for seven years, specialising in finance, equities and analysis. She has interviewed former Prime Ministers of Australia, Tony Abbott, Julia Gillard and Kevin Rudd and ex Treasurer Jo Hockey. Jessica has worked as a journalist with Sky News Business, ABC 1, ABC's The Business, ABC24 and has also been a regional Channel 7 and 9 TV reporter with Prime7 and Win News.